Allogene Therapeutics Sees Unusually High Options Volume (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) saw unusually large options trading on Wednesday. Traders acquired 4,437 put options on the company. This is an increase of approximately 356% compared to the typical volume of 972 put options.

Insider Buying and Selling

In related news, EVP Zachary Roberts sold 35,700 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president directly owned 581,166 shares of the company’s stock, valued at $1,028,663.82. This trade represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Earl Martin Douglas sold 22,900 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total transaction of $40,304.00. Following the sale, the senior vice president directly owned 564,948 shares in the company, valued at $994,308.48. This trade represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 278,452 shares of company stock worth $534,053 over the last three months. Company insiders own 13.20% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors have recently added to or reduced their stakes in ALLO. Primecap Management Co. CA increased its stake in shares of Allogene Therapeutics by 23.8% during the third quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock valued at $8,778,000 after buying an additional 1,360,168 shares during the period. Aberdeen Group plc grew its position in shares of Allogene Therapeutics by 82.4% in the 3rd quarter. Aberdeen Group plc now owns 1,582,265 shares of the company’s stock worth $1,962,000 after buying an additional 715,015 shares during the period. AustralianSuper Pty Ltd purchased a new stake in shares of Allogene Therapeutics in the 3rd quarter worth about $474,000. Patient Square Capital LP grew its position in shares of Allogene Therapeutics by 13.1% in the 3rd quarter. Patient Square Capital LP now owns 2,981,396 shares of the company’s stock worth $3,697,000 after buying an additional 346,396 shares during the period. Finally, R Squared Ltd raised its stake in Allogene Therapeutics by 40.5% during the fourth quarter. R Squared Ltd now owns 86,215 shares of the company’s stock valued at $118,000 after buying an additional 24,842 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Key Stories Impacting Allogene Therapeutics

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: HC Wainwright raised quarterly and full‑year EPS forecasts, reiterated a “Buy” rating and a $12 price target — analysts trimmed loss expectations for 2026, signaling improved near‑term operational outlooks. HC Wainwright Research Note
• Positive Sentiment: Jefferies bumped its price target to $10 and kept a Buy rating, and Robert W. Baird raised its target to $9 — multiple broker upgrades lift sentiment and create momentum for upside expectations. Jefferies/Price Target Coverage
• Positive Sentiment: Allogene published preclinical data for ALLO‑329 in Nature Communications (dual CD19/CD70 allogeneic CAR‑T for autoimmune disease), a validation point for pipeline breadth outside oncology that can support longer‑term value. ALLO-329 Nature Communications Publication
• Neutral Sentiment: High volume of investor call purchases reported recently, indicating speculative/leveraged bullish interest that can amplify moves but is not a guarantee of fundamental improvement. Options Volume Report
• Negative Sentiment: Allogene closed an underwritten offering that raised ~$200.4M (87.5M shares at $2.00 plus option exercise). While the proceeds extend runway for trials and R&D, the large issuance is dilutive and has been cited as the catalyst for recent selloffs. Offering Closing Press Release
• Negative Sentiment: Unusual put-option activity and reports that the stock fell sharply after the equity raise indicate some investors are hedging or taking bearish positions tied to dilution and execution risk. Market Reaction to Equity Raise

Analysts Set New Price Targets

Several research firms recently commented on ALLO. Sanford C. Bernstein lifted their target price on shares of Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday. Piper Sandler upped their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 13th. JPMorgan Chase & Co. raised Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research report on Thursday. Finally, UBS Group began coverage on shares of Allogene Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Allogene Therapeutics Stock Up 9.2%

Allogene Therapeutics stock opened at $2.37 on Friday. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $4.46. The business has a 50-day simple moving average of $2.33 and a 200 day simple moving average of $1.72. The stock has a market cap of $577.76 million, a price-to-earnings ratio of -2.72 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Thursday, March 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. On average, research analysts anticipate that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.